Drug Trial Radar · NCT03118570
A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804
Last checked: Nov 19, 2026Latest source record: Jul 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
112
Actual
Start
Sep 11, 2017
Primary completion
Oct 1, 2019
Study completion Nov 12, 2020
Sponsor
- Lead sponsor
- Ultragenyx Pharmaceutical IncIndustry
- Sponsor type
- Industry
- Collaborators
- Mereo BioPharma
- First posted
- Apr 18, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to select a suitable dose of BPS804 by measuring the strength/quality of bone using a special type of CT scanner. Participants will be treated for 12 months and followed up for a further 12 months.
Conditions
- Osteogenesis Imperfecta, Type I
- Osteogenesis Imperfecta Type III
- Osteogenesis Imperfecta Type IV
Interventions
setrusumabDrug
Intravenous infusion
CalciumDietary supplement
tablets
Vitamin DDietary supplement
capsules
zoledronic acid (optional)Drug
Following completion of the study treatment (Month 12) participants can receive an optional single dose of zoledronic acid. Participants can receive an optional further dose of zoledronic acid at Month 18 at the discretion of their treating physician.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Radial Trabecular Volumetric Bone Mineral Density (Tr vBMD) at Month 12Time frame: Baseline, Month 12 (end of treatment [EOT])
- Change From Baseline in Radial Bone Strength (Failure Load) at Month 12Time frame: Baseline, Month 12 (EOT)
- Change From Baseline in Radial Bone Strength (Stiffness) at Month 12Time frame: Baseline, Month 12 (EOT)
Locations
25 sites in 5 countries. Site status is shown where the registry gives one.
Mereo Investigator Site
Birmingham, Alabama
Mereo Investigator Site
Jacksonville, Florida
Mereo Investigator Site
Baltimore, Maryland
Mereo Investigator Site
Boston, Massachusetts
Mereo Investigator Site
Saint Paul, Minnesota
Mereo Investigator Site
St Louis, Missouri
Mereo Investigator Site
Albuquerque, New Mexico
Mereo Investigator Site
Cincinnati, Ohio
Mereo Investigator Site
Portland, Oregon
Mereo Investigator Site
Pittsburgh, Pennsylvania
Mereo Investigator Site
Nashville, Tennessee
Mereo Investigator Site
Houston, Texas
Mereo Investigator Site
Toronto, Ontario, Canada
Mereo Investigator Site
Montreal, Quebec, Canada
Mereo Investigator Site
Québec, Quebec, Canada
Mereo Investigator Site
Aarhus, Denmark
Mereo Investigator Site
Odense, Denmark
Mereo Investigator Site
Lyon, France
Mereo Investigator Site
Paris, France
Mereo Investigator Site
Paris, Paris Cedex 14, France
Mereo Investigator Site
Bristol, United Kingdom
Mereo Investigator Site
London, United Kingdom
Mereo Investigator Site
Cambridge, Cambridgeshire, United Kingdom
Mereo Investigator Site
Newcastle upon Tyne, Newcastle, United Kingdom
Mereo Investigator Site
Oxford, Oxfordshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.